The WP1 InnoThyroGen completed milestone marks a major step forward in shaping a cross-border personalised medicine ecosystem for thyroid disease. Led by Prof. Tatijana Zemunik (University of Split School of Medicine – MEFST), WP1 established the scientific and strategic basis for long-term Croatian-Serbian collaboration in genomics and predictive healthcare.
Through this work package, the consortium defined how key stakeholders clinicians, researchers, patients, industry, public health authorities, and policymakers – will be involved throughout the project to ensure successful development, validation, and implementation of personalised medicine solutions.
Purpose of WP1
The main objective of WP1 was to create a collaborative R&I framework that enables development and adoption of advanced personalised tools for thyroid disease care in Croatia and Serbia.
This includes:
- mapping all relevant stakeholder groups,
- defining engagement methodologies,
- analysing ecosystem barriers and innovation potential,
- developing a joint cross-border R&I strategy.
What has been achieved?
WP1 consisted of four tasks – all successfully delivered.
T1.1 – Stakeholder definition & engagement methodology
Designed a comprehensive stakeholder framework and executed engagement activities including:
- surveys, interviews, and focus groups,
- participatory workshops in Split and Belgrade,
- co-creation processes aligned with real healthcare needs.
T1.2 – Knowledge Base development
Defined the structure, content pathways, and usability design for the InnoThyroGen Knowledge Base, which will include:
- scientific literature and clinical insights,
- regulatory and ethical guidance,
- implementation and infrastructure requirements.
T1.3 – Mapping barriers & opportunities
A full analysis of the two national ecosystems identified:
- unequal access to sequencing infrastructure,
- fragmentation of genomic expertise and HPC capacities,
- gaps in funding exploitation and mobility mechanisms,
- but also strong opportunities for joint growth and synergy.
T1.4 – Joint Cross-Border R&I Strategy
Developed a unified strategic roadmap aligned with:
- EP PerMed SRIA objectives
- Croatian and Serbian Smart Specialisation Strategies (S3)
This supports innovation deployment and future clinical pilots under WP4.
Deliverables submitted under WP1
| Deliverable | Description | Status |
|---|---|---|
| D1.1 Knowledge Base & Stakeholder Engagement Methodology | stakeholder structure, engagement tools, barriers & requirements | ✔ Submitted |
| D1.2 Joint Cross-Border R&I Strategy in Personalised Medicine | policy and implementation roadmap for HR-RS collaboration | ✔ Submitted |
Why is WP1 important?
WP1 is the foundation on which the entire project will continue to grow. It enables:
- development of the Regional Personalised Medicine Ecosystem (WP2),
- execution of pilot-projects in real clinical settings (WP4),
- structured knowledge transfer and capacity building (WP3),
- continuous engagement of patients and end users (WP6).
By completing WP1, InnoThyroGen is now fully ready to move into its implementation and impact phase.
Stay Connected
Follow us on social media for updates, events, and project news.
